SECURITIES EXCHANGE AGREEMENTSecurities Exchange Agreement • November 13th, 2012 • Tg Therapeutics, Inc. • Pharmaceutical preparations
This Securities Exchange Agreement (this “Agreement”) is made as of November 9, 2012 by and between LFB Biotechnologies S.A.S., a company organized under the laws of France with a principal place of business at 3 avenue des Tropiques, B.P. 305-Les Ulis- 91958, Courtaboeuf Cedex, France (“Purchaser”), and TG Therapeutics, Inc., a Delaware corporation with a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019 (the “Company”).
